As many have reported on this unique case of a possible functional cure in the Mississippi child, researchers theorize that antiviral drugs prevented the formation of so-called viral reservoirs that harbor the virus. These reservoirs have been the key stumbling block to a cure because even though AIDS drugs stop HIV from replicating, the virus lurks in the reservoirs, ready to come surging (re-emerging) back when treatment is stopped. See the the Wall Street Journal article

It is our opinion based on published data, that GenePro has the promise of generating long term immune memory cells that can kill the re-emerging virus. Please see: GenePro Paper

Further studies in humans are required based on published studies in animals.

ImmunoGenetix Therapeutics, Inc. is a biotechnology company developing advanced DNA immunotherapies for HIV infection.  DNA immunotherapies offer a promising approach to reducing the dependency on anti-HIV drug cocktails and diminishing the emergence of drug-resistant HIV strains.  They are relatively inexpensive to produce, readily scaled up, and stable at ambient temperatures.

GenePro™ (∆4SHIVku2), the Company’s lead product candidate incorporates a proprietary DNA construct that yields high levels of gene expression and non-infectious HIV protein production, and induces a robust antibody and cellular immune response in animal models.  In preclinical efficacy studies, this immunotherapeutic candidate controlled viral replication and provided protection against a deadly AIDS causing virus in monkeys without viral protein boosts and without anti-viral therapy.

GenePro™ (∆4SHIVku2)

The ImmunoGenetix lead product candidate, GenePro™, uses a DNA composition developed through animal passaging.  This approach generates superior gene expression and subsequent non-infectious HIV protein production activity, which results in an enhanced immune response.  GenePro™ stimulates a potent cellular and antibody response that can control the replication of a deadly AIDS-causing virus in primate animal models without protein or viral vector boosts and without anti-viral therapy.